OTCMKTS:MDITCytocore Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cytocore Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.03 +0.00 (+0.37 %) (As of 04/10/2020 05:36 AM ET) Add Compare Share Today's Range$0.03Now: $0.03▼$0.0350-Day Range$0.03MA: $0.04▼$0.0552-Week Range$0.01Now: $0.03▼$0.12Volume500 shsAverage Volume10,821 shsMarket Capitalization$2.31 millionP/E RatioN/ADividend YieldN/ABeta3.07 ProfileAdvanced ChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cytocore. Previous Next 2.5 Community Rank Outperform VotesCytocore has received 68 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCytocore has received 66 “underperform” votes. (Add your “underperform” vote.)Community SentimentCytocore has received 50.75% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cytocore and other stocks. Vote “Outperform” if you believe MDIT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDIT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCytocore does not currently pay a dividend.Dividend GrowthCytocore does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytocore insiders have not sold or bought any company stock.Percentage Held by Insiders85.40% of the stock of Cytocore is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.70 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MDIT Previous Symbol CUSIPN/A CIK75439 Webhttp://www.medite-group.com/ Phone407-996-9630Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.81 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees69 Outstanding Shares85,828,000Market Cap$2.31 million Next Earnings DateN/A OptionableNot Optionable Receive MDIT News and Ratings via Email Sign-up to receive the latest news and ratings for MDIT and its competitors with MarketBeat's FREE daily newsletter. OTC:MDIT Rates by TradingView Cytocore (OTCMKTS:MDIT) Frequently Asked Questions How has Cytocore's stock been impacted by COVID-19 (Coronavirus)? Cytocore's stock was trading at $0.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDIT stock has decreased by 32.8% and is now trading at $0.0269. View which stocks have been most impacted by Coronavirus. Has Cytocore been receiving favorable news coverage? Media headlines about MDIT stock have been trending very negative on Friday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cytocore earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutCytocore. Who are some of Cytocore's key competitors? Some companies that are related to Cytocore include Dynatronics (DYNT), Lianluo Smart (LLIT), Avinger (AVGR), PlusTherapeuticsInc . (PSTV), Encision (ECIA), Obalon Therapeutics (OBLN), Hancock Jaffe Laboratories (HJLI), CELLECT BIOTECH/S (APOP), AdvanSource Biomaterials Corpration (ASNB), Sintx Technologies (SINT), Regenicin (RGIN), Neurometrix (NURO), Hypertension Diagnostics (HDII), Invivo Therapeutics (NVIV) and Valeritas (VLRXQ). What other stocks do shareholders of Cytocore own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytocore investors own include Entegris (ENTG), DarioHealth (DRIO), Cracker Barrel Old Country Store (CBRL), Bank of Marin Bancorp (BMRC), Adaptimmune Therapeutics (ADAP), Warehouse REIT (WHR), Draper Esprit (GROW), Rational (RAA), Pfeiffer Vacuum Technology (PFV) and Banyan Gold (BYN). Who are Cytocore's key executives? Cytocore's management team includes the following people: Mr. Jeffrey Rencher, Chief Marketing & Bus. Devel. Officer (Age 52)Ms. Susan Weisman, Consultant (Age 58)Mr. Elmar A. Dave, Chief Exec. Officer What is Cytocore's stock symbol? Cytocore trades on the OTCMKTS under the ticker symbol "MDIT." How do I buy shares of Cytocore? Shares of MDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cytocore's stock price today? One share of MDIT stock can currently be purchased for approximately $0.03. How big of a company is Cytocore? Cytocore has a market capitalization of $2.31 million and generates $6.81 million in revenue each year. Cytocore employs 69 workers across the globe. View additional information about Cytocore. What is Cytocore's official website? The official website for Cytocore is http://www.medite-group.com/. How can I contact Cytocore? Cytocore's mailing address is 4203 SW 34TH STREET, ORLANDO FL, 32811. The company can be reached via phone at 407-996-9630 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Why do commodities matter?
